Immunoregulation by resveratrol; implications for normal tissue protection and tumour suppression

Clinical and Experimental Pharmacology and Physiology, Journal Year: 2023, Volume and Issue: 50(5), P. 353 - 368

Published: Feb. 14, 2023

Immune reactions are involved in both tumour and normal tissue response to therapy. Elevated secretion of certain chemokines, exosomes cytokines triggers inflammation, pain, fibrosis ulceration among other side effects. On the hand, tumour-promoting molecules suppresses activity anticancer immune cells facilitates proliferation malignant cells. Novel drugs such as checkpoint inhibitors (ICIs) boost immunity via inducing natural killer (NK) CD8+ T lymphocytes. Certain chemotherapy radiotherapy may induce tumour, however, have severe effects for tissues through stimulation several responses. Thus, administration products with low be a promising approach modulate system organs. Resveratrol is well-known phenol diverse on tumours. To date, large number experiments confirmed potential resveratrol an adjuvant. This review focuses ensuing or suppression responses after drugs. Later on, immunoregulatory following exposure agents will discussed.

Language: Английский

---

The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 162, P. 114646 - 114646

Published: April 1, 2023

Extending the durability of response is current focus in cancer immunotherapy with immune checkpoint inhibitors (ICIs). However, factors like non-immunogenic tumor microenvironment (TME) along aberrant angiogenesis and dysregulated metabolic systems are negative contributors. Hypoxia a key TME condition critical promoter hallmarks. It acts on non-immune cells within order for promoting evasion therapy resistance. Extreme hypoxia major resistance to programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor therapy. inducible factor-1 (HIF-1) as mediator anti-PD-(L)1. Targeting or HIF-1 can thus be an effective strategy reinvigoration cellular immunity against cancer. Among various strategies presented so far, over vascular normalization, which approach highly reducing rate hypoxia, increasing drug delivery into area, boosting efficacy

Language: Английский

---

B7-H3 immunoregulatory roles in cancer

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 163, P. 114890 - 114890

Published: May 15, 2023

B7 homolog 3 (B7-H3, also called CD276) is a checkpoint of family that aberrantly and consistently expressed in several human cancers, its overexpression correlates with weak prognosis. B7-H3 on number cells, it acts as driver immune evasion. This mediated through hampering T cell infiltration promoting exhaustion CD8+ cells. Increased activity promotes macrophage polarity toward pro-tumor type 2 (M2) phenotype. In addition, high induces aberrant angiogenesis to promote hypoxia, result which resistance common inhibitor (ICI) therapy. the impact hypoxia dampening recruitment into tumor area. The immunosuppressive property offers insights targeting this desired approach cancer immunotherapy. can be target blocking monoclonal antibodies (mAbs), combination therapies, chimeric antigen receptor-modified (CAR-T) cells bispecific antibodies.

Language: Английский

---

Mechanisms of CD8+ T cell exclusion and dysfunction in cancer resistance to anti-PD-(L)1

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 163, P. 114824 - 114824

Published: May 2, 2023

CD8+ T cells are the front-line defensive against cancer. Reduced infiltration and effector function of occurs in cancer is contributed to defective immunity immunotherapy resistance. Exclusion exhaustion two key factors associated with reduced durability immune checkpoint inhibitor (ICI) therapy. Initially activated upon exposure chronic antigen stimulation or immunosuppressive tumor microenvironment (TME) acquire a hyporesponsive state that progressively lose their function. Thus, strategy look for cell Targeting such can define promising supplementary approach patients receiving anti-programmed death-1 receptor (PD-1)/anti-programmed death-ligand 1 (PD-L1) Recently, bispecific antibodies developed PD-(L)1 dominant factor within TME, representing higher safety profile exerting more desired outcomes. The focus this review discuss about promoters deficient addressing ICI

Language: Английский

---

Frontiers and future of immunotherapy for pancreatic cancer: from molecular mechanisms to clinical application

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: May 2, 2024

Pancreatic cancer is a highly aggressive malignant tumor, that becoming increasingly common in recent years. Despite advances intensive treatment modalities including surgery, radiotherapy, biological therapy, and targeted the overall survival rate has not significantly improved patients with pancreatic cancer. This may be attributed to insidious onset, unknown pathophysiology, poor prognosis of disease. It therefore essential identify develop more effective safer treatments for Tumor immunotherapy new fourth pillar anti-tumor therapy after chemotherapy. Significant progress made use wide variety tumors years; breakthrough also been review describes immune checkpoint inhibitors, vaccines, adoptive cell oncolytic virus, matrix-depletion therapies At same time, some potential biomarkers combinations are discussed. The molecular mechanisms various immunotherapies have elucidated, their clinical applications highlighted. current challenges associated proposed strategies hold promise overcoming these limitations discussed, aim offering insights into

Language: Английский

---

Interleukin-2 therapy of cancer-clinical perspectives

International Immunopharmacology, Journal Year: 2021, Volume and Issue: 98, P. 107836 - 107836

Published: July 1, 2021

Language: Английский

---

Organ Tropism in Solid Tumor Metastasis: An Updated Review

Future Oncology, Journal Year: 2021, Volume and Issue: 17(15), P. 1943 - 1961

Published: March 17, 2021

Tumors are equipped with a highly complex machinery of interrelated events so as to adapt hazardous conditions, preserve growing cell mass and thrive at the site metastasis. Tumor cells display metastatic propensity toward specific organs where stromal milieu is appropriate for their further colonization. Effective colonization relies on plasticity tumor in adapting conditions new area by reshaping epigenetic landscape. Breast cancer cells, instance, able adopt brain-like or epithelial/osteoid features order pursue effective metastasis into brain bone, respectively. The aim this review discuss recent insights organ tropism metastasis, outlining potential strategies address driver aggressiveness.

Language: Английский

---

Normalization in tumor ecosystem: Opportunities and challenges

Cell Biology International, Journal Year: 2021, Volume and Issue: 45(10), P. 2017 - 2030

Published: June 30, 2021

Current research in cancer therapy aims to exploit efficient strategies have long-lasting effects on tumors and reduce or even revoke the chance of recurrence. Within tumor stroma, O2 nutrients are abnormally distributed between various cells (preferentially for supplying cells), immune contexture is positioned (permissive essentially exhibiting tumor-promoting capacity), fibroblast fibrotic content (presence both extracellular matrix [ECM] stiffening ECM-degrading factors purposes), vasculature orchestrated (for hindering drug delivery increasing metastasis). Resistance actually an adaptive response imbalance ecosystem; thus, key consideration effective bring back normal status this ecosystem so as reach desired durable outcome. Vascular normalization, metabolic modulation (glucose particular), balancing cellular dispersion, pH rate within microenvironment suggested reverse abnormality stroma.

Language: Английский

---

Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy

Cellular Oncology, Journal Year: 2022, Volume and Issue: 45(3), P. 333 - 353

Published: May 19, 2022

Language: Английский

---

Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes

Journal of Nanobiotechnology, Journal Year: 2022, Volume and Issue: 20(1)

Published: Sept. 15, 2022

The chemotherapy effect of docetaxel (DTX) against triple-negative breast cancer (TNBC) remains mediocre and limited when encapsulated in conventional cholesterol liposomes, mainly ascribed to poor penetration immunosuppressive tumor microenvironment (TME) caused by stroma cells, especially cancer-associated fibroblasts (CAFs). Many studies have attempted address these problems but trapped into the common dilemma excessively complicated formulation strategies at expense druggability as well clinical translational feasibility. To better discrepancy, ginsenoside Rg3 was utilized substitute develop a multifunctional DTX-loaded liposome (Rg3-Lp/DTX). obtained Rg3-Lp/DTX proved be preferentially uptake 4T1 cells accumulate more site via interaction between glycosyl moiety exposed on surface glucose transporter1 (Glut1) overexpressed cells. After reaching site, shown reverse activated CAFs resting stage attenuate dense barrier suppressing secretion TGF-β from regulating TGF-β/Smad signaling. Therefore, reduced levels collagens were found TME after incorporation Rg3, inducing enhanced reversed immune system which can detect neutralize Compared with wooden smart versatile could significantly improve anti-tumor DTX, providing promising approach for TNBC therapy excellent therapeutic efficacy simple preparation process.

Language: Английский

---